Historically seen as a "platform monetization story," according to one analyst, Ionis now has a potential multibillion-dollar ...
Ionis Pharmaceuticals IONS signed a license agreement with Japan-based Ono Pharmaceutical. Per the terms, Ono has acquired exclusive global rights from IONS to develop and market sapablursen, an ...
Jonathan Wosen is STAT’s West Coast biotech & life sciences reporter. You can reach Jonathan on Signal at jwosen.27. Ionis Pharmaceuticals won approval from the Food and Drug Administration on ...
After 35 years engaged in the research and development of pharmaceutical products, Ionis began marketing its drugs for the ...
A genetic medicine from Ionis Pharmaceuticals designed to reduce high levels of cholesterol has achieved the main goal of a Phase 2 study, but the results are short of what partner AstraZeneca hoped ...
Add Yahoo as a preferred source to see more of our stories on Google. FILE PHOTO: Illustration shows a test tube in front of displayed Biogen logo (Reuters) - Biogen and Ionis Pharmaceuticals said on ...
Ionis Pharmaceuticals, a California company that pioneered a whole class of RNA-targeted medicines, reported on Friday that a pair of late-stage trials showed that its experimental therapy for ...
Zacks Investment Research on MSN
IONS out-licenses ex-US rights for rare neurology drug to Recordati
Ionis Pharmaceuticals IONS signed a license agreement with Italy-based Recordati. Per the terms, Recordati will acquire ...
Jan 22 (Reuters) - Ionis Pharmaceuticals (IONS.O), opens new tab said on Monday its experimental drug reduced the occurrence of painful attacks in patients with a rare genetic disease that triggers ...
The U.S. Food and Drug Administration (FDA) approved on Wednesday Ionis Pharmaceuticals, Inc.’s IONS Tryngolza (olezarsen) to ...
CARLSBAD, Calif.--(BUSINESS WIRE)-- Ionis Pharmaceuticals, Inc. (Nasdaq: IONS) today announced that the U.S. Food and Drug Administration (FDA) has accepted for Priority Review the New Drug ...
Narrow-moat Ionis’ third-quarter results are in line with our expectations. We are maintaining our $69 fair value estimate, and we believe the company is ready for its first two independent US drug ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results